

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)



(10) International Publication Number
WO 2022/232411 A2

(51) International Patent Classification:

C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61K 31/712 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/US2022/026760

(22) International Filing Date:

28 April 2022 (28.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/181,023	28 April 2021 (28.04.2021)	US
63/320,651	16 March 2022 (16.03.2022)	US
63/334,496	25 April 2022 (25.04.2022)	US

(71) Applicant: **EISAI R&D MANGEMENT CO., LTD.**
[JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo
112-8088 (JP).

(72) Inventors: **VATHIPADIEKAL, Vinod**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **MITASEV, Branko**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **EASLEY-NEAL, Courtney**; 35 Cambridgepark Dr., Suite 200,

Cambridge, Massachusetts 02140 (US). **CHOI, Hyeon Wook**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **FANG, Frank**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **WANG, John**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **VEMULA, Praveen**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US). **LEE, Jung Hwa**; 35 Cambridgepark Dr., Suite 200, Cambridge, Massachusetts 02140 (US).

(74) Agent: **HEMMELGARN, Benjamin T.**; FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS




FIG. 1

(57) Abstract: Novel antisense oligonucleotides that induce Exon-2 skipping in the *CD33* gene during pre-mRNA splicing, and their use in the treatment of a neurodegenerative disease, such as Alzheimer's disease, are disclosed.

[Continued on next page]

WO 2022/232411 A2

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*